Literature DB >> 30601254

Shadows Behind Using Simple Risk Models in Selection of Hepatocellular Carcinoma Patients for Liver Transplantation.

Michał Grąt1, Jan Stypułkowski1, Marcin Morawski1, Karolina M Wronka2, Michał Wasilewicz2, Zbigniew Lewandowski3, Karolina Grąt4, Zofia Wójcik1, Waldemar Patkowski1, Krzysztof Zieniewicz1.   

Abstract

OBJECTIVE: To assess the potential influence of replacing Milan criteria with simple risk scores on outcomes of hepatocellular carcinoma (HCC) patients undergoing liver transplantation. SUMMARY BACKGROUND DATA: Several risk scores combining morphological and biological features were recently proposed for precise selection of HCC patients for transplantation.
METHODS: This retrospective study included 282 HCC liver transplant recipients. Recurrence-free survival (RFS), the primary outcome measure, was evaluated according to Metroticket 2.0 model and French AFP model with Milan criteria serving as benchmark.
RESULTS: Patients were well stratified with respect to RFS by Milan criteria, Metroticket 2.0 criteria, and AFP model cut-off ≤2 points (all P < 0.001) with c-statistics of 0.680, 0.695, and 0.681, respectively. Neither Metroticket 2.0 criteria (0.014, Z = 0.023; P = 0.509) nor AFP model (-0.014, Z = -0.021; P = 0.492) provided significant net reclassification improvement. Both patients within the Metroticket 2.0 criteria and AFP model ≤2 points exhibited heterogeneous recurrence risk, dependent upon alpha-fetoprotein (P = 0.026) and tumor number (P = 0.024), respectively. RFS of patients beyond Milan but within Metroticket 2.0 criteria (75.3%) or with AFP model ≤2 points (74.1%) was inferior to that observed for patients within Milan criteria (87.1%; P = 0.067 and P = 0.045, respectively). Corresponding microvascular invasion rates were 37.2% and 50.0%, compared with 13.6% in patients within Milan criteria (both P < 0.001). Moreover, Milan-out status was associated with significantly higher recurrence risk in subgroups within Metroticket 2.0 criteria (P = 0.021) or AFP model ≤2 points (P = 0.014).
CONCLUSION: Utilization of simple risk scores for liver transplant eligibility assessment leads to selection of patients at higher risk of posttransplant HCC recurrence.

Entities:  

Mesh:

Year:  2020        PMID: 30601254     DOI: 10.1097/SLA.0000000000003176

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  6 in total

1.  Pre-transplant alpha-fetoprotein is associated with post-transplant hepatocellular carcinoma recurrence mortality.

Authors:  Nadim Mahmud; Binu John; Tamar H Taddei; David S Goldberg
Journal:  Clin Transplant       Date:  2019-06-25       Impact factor: 2.863

2.  Striving for decreased post-transplant hepatocellular carcinoma recurrence without excluding potentially curable patients: the utility of tumor biology.

Authors:  Russell Evan Rosenblatt; Karim Jarir Halazun
Journal:  Hepatobiliary Surg Nutr       Date:  2019-10       Impact factor: 7.293

3.  Impact of Body Composition on the Risk of Hepatocellular Carcinoma Recurrence After Liver Transplantation.

Authors:  Karolina Grąt; Ryszard Pacho; Michał Grąt; Marek Krawczyk; Krzysztof Zieniewicz; Olgierd Rowiński
Journal:  J Clin Med       Date:  2019-10-13       Impact factor: 4.241

4.  Prognostic role of selection criteria for liver transplantation in patients with hepatocellular carcinoma: a network meta-analysis.

Authors:  Vladimir J Lozanovski; Ali Ramouz; Ehsan Aminizadeh; Sadeq Ali-Hasan Al-Saegh; Elias Khajeh; Heike Probst; Susanne Picardi; Christian Rupp; De-Hua Chang; Pascal Probst; Arianeb Mehrabi
Journal:  BJS Open       Date:  2022-01-06

5.  When to call it off: defining transplant candidacy limits in liver donor liver transplantation for hepatocellular carcinoma.

Authors:  Abu Bakar Hafeez Bhatti; Ammal Imran Qureshi; Rizmi Tahir; Faisal Saud Dar; Nusrat Yar Khan; Haseeb Haider Zia; Shahzad Riyaz; Atif Rana
Journal:  BMC Cancer       Date:  2020-08-12       Impact factor: 4.430

6.  Potentiality of α-fetoprotein (AFP) and soluble intercellular adhesion molecule-1 (sICAM-1) in prognosis prediction and immunotherapy response for patients with hepatocellular carcinoma.

Authors:  Weiwei Cao; Yu Chen; Wei Han; Juzheng Yuan; Weimin Xie; Kun Liu; Yan Qiu; Xudan Wang; Xiao Li
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.